Stroke trials: What have we learned?

Abstract We reviewed the recent, major, therapeutic trials of intravenous thrombolytic therapy and ancrod for ischemic stroke. Randomized, controlled studies of acute ischemic stroke treatment were reviewed. Several post-FDA approval intravenous tPA studies were reviewed to understand the experience of this medication in practice. STAT trial was the major study using ancrod. Of multiple intravenous thrombolytic studies, the NINDS study of intravenous tPA was the only study to demonstrate a significantly higher percentage of patients with complete recovery or minimal deficit at three months. Studies in communities utilizing intravenous tPA for stroke illustrate the need for close adherence to the NINDS study protocol or else the risk of tPA use may exceed the benefits. [Neurol Res 2002; 24: S27-S32]

[1]  Stephen Rose,et al.  Diffusion‐ and perfusion‐weighted MRI response to thrombolysis in stroke , 2002, Annals of neurology.

[2]  J. Grotta,et al.  Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. , 2001, JAMA.

[3]  A. Alexandrov,et al.  Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. , 2001, Archives of neurology.

[4]  P. Marx,et al.  Intravenous tPA for Ischemic Stroke: Team Performance Over Time, Safety, and Efficacy in a Single-Center, 2-Year Experience , 2001, Stroke.

[5]  M. Hennerici,et al.  Outcomes of ancrod in acute ischemic stroke. Independent Data and Safety Monitoring Board for ESTAT. Steering Committee for ESTAT. European Stroke Treatment with Ancrod Trial. , 2000, JAMA.

[6]  W. Heiss,et al.  One-year follow-Up in acute stroke patients treated with rtPA in clinical routine. , 2000, Stroke.

[7]  H. Köhler.  Book Review Comprehensive Clinical Nephrology By Richard J. Johnson and John Feehally. Approximately 700 pp., illustrated. St. Louis, Mosby, 2000. $189. 0-7234-3117-5 , 2000 .

[8]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[9]  D. Levy,et al.  Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. , 2000, JAMA.

[10]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[11]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[12]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[13]  J. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. , 1999, The New England journal of medicine.

[14]  Joseph P. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year , 1999 .

[15]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[16]  L Bozzao,et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy. , 1997, Radiology.

[17]  B. Elger,et al.  MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats. , 1997, European journal of pharmacology.

[18]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, Journal of the American Medical Association (JAMA).

[19]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[20]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[21]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[22]  J. Baron,et al.  Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. , 1995, Stroke.

[23]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[24]  Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. , 1995, Lancet.

[25]  A. Yamadori,et al.  Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke , 1992, Neurology.

[26]  T. Brott,et al.  Use of ancrod in acute or progressing ischemic cerebral infarction. , 1988, Annals of emergency medicine.

[27]  W. Heiss,et al.  Controlled trial of ancrod in ischemic stroke. , 1983, Archives of neurology.